Wang, Lu
Tan, Tze King http://orcid.org/0000-0003-1623-615X
Durbin, Adam D. http://orcid.org/0000-0002-5472-9847
Zimmerman, Mark W. http://orcid.org/0000-0003-2489-3889
Abraham, Brian J. http://orcid.org/0000-0001-8085-3027
Tan, Shi Hao
Ngoc, Phuong Cao Thi http://orcid.org/0000-0002-3059-9179
Weichert-Leahey, Nina
Akahane, Koshi http://orcid.org/0000-0001-8591-1281
Lawton, Lee N.
Rokita, Jo Lynne http://orcid.org/0000-0003-2171-3627
Maris, John M.
Young, Richard A. http://orcid.org/0000-0001-8855-8647
Look, A. Thomas
Sanda, Takaomi http://orcid.org/0000-0003-1621-4954
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA157951)
National Research Foundation Singapore (NRF-NRFF2013-02)
Ministry of Education - Singapore (FRC T1-2015 Sep -07)
Article History
Received: 8 January 2019
Accepted: 11 November 2019
First Online: 9 December 2019
Competing interests
: R.A.Y. is a founder and shareholder of Syros Pharmaceuticals, which is discovering and developing therapeutics directed at transcriptional pathways in cancer. B.J.A. is a shareholder of Syros Pharmaceuticals. No other potential conflicts of interest are declared.